Real‐life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis

Abstract

Letters the Editor e575Dear Editor, Skin ageing is accelerated during menopause; however, many women and healthcare professionals are insufficiently informed on the impact of menopause on skin. 1 Declining oestrogen detrimentally impacts the skin's extracellular matrix (ECM),

Generalized Pustular Psoriasis and Plaque Psoriasis Successfully Treated with Ixekizumab

“…Ixekizumab is an anti-IL-17A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis in Europe and the United States. In Japan, ixekizumab has been successfully used also in patients affected by GPP, in both clinical trials [6] and real-life case series [7]. This level of response was sustained with continued treatment over three years [8].…”

“…However, data on this population are limited to very small groups of patients. We decided to prescribe ixekizumab for various reasons: first, the presence of some data regarding the management of GPP with ixekizumab [7]; second, our favorable experience with this drug, also in patients with multiple comorbidities, such as previous malignancies [9] and serological evidence of viral hepatitis [10]; third, the rapid onset of action of ixekizumab, as the patient's quality of life was greatly affected by the disease.…”

Ixekizumab treatment for drug‐induced erythrodermic psoriasis

“…important because of potential life-threatening complications. 2 Here, we present a case of EP probably triggered by enalapril with excellent response to ixekizumab. In addition, a narrative review of EP treatment with ixekizumab is provided.…”

“…They could not confirm ixekizumab efficacy as only three patients were included and just one completed 12 weeks treatment, without achieving PASI 90 after 48 weeks. 2 In a nine-case-series of EP refractory to secukinumab 77.8% achieved PASI 50, 44.4% PASI 75 and 11.1% PASI 100 by week 12. The only adverse effect reported was inyection-site reaction.…”

Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry

“…The advent of biologic agents over nearly two decades has dramatically enhanced the treatment of moderate to severe psoriasis. Data from randomized controlled trials (RCTs) [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16] have demonstrated that these agents can be highly efficacious. Yet the preponderance of evidence has been garnered from studies that have primarily included White patients.…”